

Attachment # 6

SHEET 1 OF 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MEWB25.001APC	APPLICATION NO. 09/403,440  RECEIVED  SEP 19 2000
	APPLICANT David P. Lane  TECH CENTER 1600/2900	
	FILING DATE January 19, 2000	GROUP 1614

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
ds	1	WO 93/20238	14.10.93	Patent Cooperation Treaty	C12Q	1/68		
	2	WO 96/02642	01.02.96	Patent Cooperation Treaty	C12Q	15/12		
	3	WO 98/01467	15.01.98	Patent Cooperation Treaty	C07K	14/00		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
ds	4	Blaydes, et al., <i>Oncogene</i> , 14:1859-1568, 1997, "tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2."
	5	Böttger, et al., <i>Oncogene</i> , 13:2141-2147, 1996, "Identification of novel mdm2 binding peptides by phage display."
	6	Chen, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 91:2684-2688, March 1994, "Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway."
	7	Colas, et al., <i>Nature</i> , 380:548-550, April 11, 1996, "Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2."
	8	Finlay, C.A., <i>Molecular and Cellular Biology</i> , 13(1):301-306, January 1993, "The mdm-2 Oncogene Can Overcome Wild-Type p53 Suppression of Transformed Cell Growth."
	9	Florenes, et al., <i>Journal of the National Cancer Institute</i> , 86(17):1297-1302, September 7, 1994, "MDM2 Gene Amplification and Transcript Levels in Human Sarcomas: Relationship to TP53 Gene Status."
	10	Haupt, et al., <i>The EMBO Journal</i> , 15(7):1596-1606, 1996, "Cell type-specific inhibition of p53-mediated apoptosis by mdm2."
	11	Hupp, et al., <i>Cell</i> , 83:237-245, October 20, 1995, "Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53."
	12	Jones, et al., <i>Nature</i> , 378:206-208, November 9, 1995, "Rescue of embryonic lethality in Mdm1-deficient mice by absence of p53."
	13	Juven, et al., <i>Oncogene</i> , 8:3411-3416, 1993, "Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene."
	14	Kovar, et al., <i>Oncogene</i> , 8:2683-2690, 1993, "Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumors."

EXAMINER M. T. Davis	DATE CONSIDERED 02/15/03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MEWB25.001APC	APPLICATION NO. 09/403,440
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		RECEIVED SEP 19 2000	
		APPLICANT David P. Lane	
		FILING DATE January 19, 2000	GROUP 1614 TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
7/8	15 Kussion et al., <i>Science</i> , 274:948-953, November 8, 1996, "Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain."
	16 LaVallie, et al., <i>Bio/Technology</i> , 11:187-193, February 11, 1993, "A Thioredoxin Gene Fusion Expression System the E. coli Cytoplasm."
	17 Lin, Y. and M. Green, <i>Nature</i> , 340:656-659, August 24, 1989, "Similarities between prokaryotic and eukaryotic cyclic AMP-responsive promoter elements."
	18 Lu, X and D. Lane, <i>Cell</i> , 75:765-778, November 19, 1993, "Differential Induction of Transcriptionally Active p53 Following UV or Ionizing Radiation: Defects in Chromosome Instability Syndromes?"
	19 Marston, et al., <i>Oncogene</i> , 9:2707-2716, 1994, "Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function."
	20 Midgley, et al., <i>Journal of Cell Science</i> , 101:183-189, 1992, "Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli."
	21 Momand, et al., <i>Cell</i> , 69:1237-1245, June 26, 1992, "The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation."
	22 Montes de Oca Luna, et al., <i>Nature</i> , 278:203-206, 1995, "Rescue of Early Embryonic Lethality in mdm1-Deficient *."
	23 Oliner, et al., <i>Nature</i> , 362:857-860, April 29, 1993, "Oncoprotein MDM1 conceals the activation domain of tumour suppressor p53."
	24 Otto A. and W. Deppert, <i>Oncogene</i> , 8:2591-2603, 1993, "Upregulation of mdm-2 expression in meth a tumor cells tolerating wild-type p53."
	25 Picksley, et al., <i>Oncogene</i> , 9:2523-2529, 1994, "Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides."
	26 Renzing, J. and D. Lane, <i>Oncogene</i> , 10:1865-1868, 1995, "p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts."
	27 Vojtesek, B. and D. Lane, <i>Journal of Cell Science</i> , 105:607-612, 1993, "Regulation of p53 protein expression in human breast cancer cell lines."
	28 Wu, et al., <i>Genes &amp; Development</i> , 7:1126-1132, 1993, "The p53-mdm-2 autoregulatory feedback loop."

W:\DOCS\GRD\GRD-3120.DOC  
081500

EXAMINER M. T. DAVIS	DATE CONSIDERED 02/15/02
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	